<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39376606</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database.</ArticleTitle><Pagination><StartPage>1472648</StartPage><MedlinePgn>1472648</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1472648</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1472648</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Lumateperone has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia in adults since 2019, however, there is still a lack of data report on adverse reactions in real-world settings. Conducting data mining on adverse events (AEs) associated with Lumateperone and investigating the risk factors for serious AEs can provide valuable insights for its clinical practice.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">AE reports in the FDA Adverse Event Reporting System (FAERS) from 2019 Q4 (FDA approval of Lumateperone) to 2024 Q1 were collected and analyzed. Disproportionality in Lumateperone-associated AEs was evaluated using the following parameters: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS). Univariate and multivariate logistic regression analyses were conducted to identify the risk factors for Lumateperone-induced severe AEs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 2,644 reports defined Lumateperone as the primary suspected drug was collected, including 739 reports classified as severe AEs and 1905 reports as non-severe AEs. The analysis revealed that 130 preferred terms (PTs) with significant disproportionality were based on the four algorithms, 67 (51.53%) of which were not included in the product labeling, affecting 6 systems and organs. In addition, dizziness (81 cases) was the most reported Lumateperone-associated severe AEs, and tardive dyskinesia showed the strongest signal (ROR = 186.24). Logistic regression analysis indicated that gender, bipolar II disorder, and concomitant drug use are independent risk factors for Lumateperone-associated severe AEs. Specifically, female patients had a 1.811-fold increased risk compared with male patients (OR = 1.811 [1.302, 2.519], <i>p</i> = 0.000), while patients with bipolar II disorder had a 1.695-fold increased risk compared with patients diagnosed with bipolar disorder (OR = 1.695 [1.320, 2.178], <i>p</i> = 0.000). Conversely, concomitant use of CYP3A4 inhibitors or drugs metabolized by CYP3A4 was associated with a decreased risk of severe AEs (OR = 0.524 [0.434, 0.633], <i>P</i> = 0.000).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Collectively, this study provides critical insights into the safety profile of Lumateperone. It highlights the need for cautious use in high-risk populations, such as females and individuals with bipolar II disorder, and emphasizes the importance of monitoring for AEs, including dizziness and tardive dyskinesia. Healthcare also should remain alert to potential AEs not listed in the prescribing information to ensure medical safety.</AbstractText><CopyrightInformation>Copyright © 2024 Zhang, Zhou, Liu, Hao, Wang, Song and Yu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yanjing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Yupei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Bingyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Technology Innovation Center for Artificial Intelligence in Clinical Pharmacy of Hebei Province, The First Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FAERS</Keyword><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">antipsychotics</Keyword><Keyword MajorTopicYN="N">lumateperone</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39376606</ArticleId><ArticleId IdType="pmc">PMC11456470</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1472648</ArticleId><ArticleId IdType="pii">1472648</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baldaçara L., Ramos A., Castaldelli-Maia J. M. (2023). Managing drug-induced psychosis. Int. Rev. Psychiatry 35 (5-6), 496–502. 10.1080/09540261.2023.2261544</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09540261.2023.2261544</ArticleId><ArticleId IdType="pubmed">38299647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate A., Lindquist M., Edwards I. R., Olsson S., Orre R., Lansner A., et al. (1998). A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54 (4), 315–321. 10.1007/s002280050466</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002280050466</ArticleId><ArticleId IdType="pubmed">9696956</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair H. A. (2020). Lumateperone: first approval. Drugs 80 (4), 417–423. 10.1007/s40265-020-01271-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01271-6</ArticleId><ArticleId IdType="pubmed">32060882</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobo W. V. (2017). The diagnosis and management of bipolar I and II disorders: clinical practice update. Mayo Clin. Proc. 92 (10), 1532–1551. 10.1016/j.mayocp.2017.06.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2017.06.022</ArticleId><ArticleId IdType="pubmed">28888714</ArticleId></ArticleIdList></Reference><Reference><Citation>Corponi F., Fabbri C., Bitter I., Montgomery S., Vieta E., Kasper S., et al. (2019). Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur. Neuropsychopharmacol. 29 (9), 971–985. 10.1016/j.euroneuro.2019.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2019.06.008</ArticleId><ArticleId IdType="pubmed">31255396</ArticleId></ArticleIdList></Reference><Reference><Citation>Correll C. U., Vanover K. E., Davis R. E., Chen R., Satlin A., Mates S. (2021). Safety and tolerability of lumateperone 42 mg: an open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophr. Res. 228, 198–205. 10.1016/j.schres.2020.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2020.12.006</ArticleId><ArticleId IdType="pubmed">33453691</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans S. J., Waller P. C., Davis S. (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 10 (6), 483–486. 10.1002/pds.677</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.677</ArticleId><ArticleId IdType="pubmed">11828828</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2015 DALYs and HALE Collaborators (2016). Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (10053), 1603–1658. 10.1016/S0140-6736(16)31460-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31460-X</ArticleId><ArticleId IdType="pmc">PMC5388857</ArticleId><ArticleId IdType="pubmed">27733283</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwood J., Acharya R. B., Marcellus V., Rey J. A. (2021). Lumateperone: a novel antipsychotic for schizophrenia. Ann. Pharmacother. 55 (1), 98–104. 10.1177/1060028020936597</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1060028020936597</ArticleId><ArticleId IdType="pubmed">32590907</ArticleId></ArticleIdList></Reference><Reference><Citation>Huhn M., Nikolakopoulou A., Schneider-Thoma J., Krause M., Samara M., Peter N., et al. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394 (10202), 939–951. 10.1016/S0140-6736(19)31135-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31135-3</ArticleId><ArticleId IdType="pmc">PMC6891890</ArticleId><ArticleId IdType="pubmed">31303314</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawad M. Y., Alnefeesi Y., Ceban F., Lui L. M. W., Jaberi S., Di Vincenzo J. D., et al. (2022). Lumateperone for the treatment of adults with schizophrenia: a systematic review. Curr. Psychiatry Rep. 24 (8), 359–368. 10.1007/s11920-022-01344-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11920-022-01344-1</ArticleId><ArticleId IdType="pubmed">35802228</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Zhou L., Shen Y., Zhou Q., Ji Y., Zhu H. (2024). Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J. Affect Disord. 346, 223–229. 10.1016/j.jad.2023.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2023.11.025</ArticleId><ArticleId IdType="pubmed">37956832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamei H. (2022). Polypharmacy management of antipsychotics in patients with schizophrenia. Med. Kaunas. 58 (11), 1584. 10.3390/medicina58111584</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58111584</ArticleId><ArticleId IdType="pmc">PMC9692600</ArticleId><ArticleId IdType="pubmed">36363541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kositsyn Y. M., de Abreu M. S., Kolesnikova T. O., Lagunin A. A., Poroikov V. V., Harutyunyan H. S., et al. (2023). Towards novel potential molecular targets for antidepressant and antipsychotic pharmacotherapies. Int. J. Mol. Sci. 24 (11), 9482. 10.3390/ijms24119482</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24119482</ArticleId><ArticleId IdType="pmc">PMC10253480</ArticleId><ArticleId IdType="pubmed">37298431</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogmann A., Peters L., von Hardenberg L., Bödeker K., Nöhles V. B., Correll C. U. (2019). Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 24 (S1), 38–69. 10.1017/S109285291900124X</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S109285291900124X</ArticleId><ArticleId IdType="pubmed">31482779</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Du Q., Guo Z., Ye X., Liu J. (2023). Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database. Front Pharmacol 14, 1283247. 10.3389/fphar.2023.1283247</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1283247</ArticleId><ArticleId IdType="pmc">PMC10667432</ArticleId><ArticleId IdType="pubmed">38027003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., Jiang Y., Du Z., Zhou Q., Shen Y., Zhu H. (2024). Multidimensional assessment of adverse events of bupropion: a large-scale data analysis from the FAERS database. J. Affect Disord. 354, 649–655. 10.1016/j.jad.2024.03.085</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2024.03.085</ArticleId><ArticleId IdType="pubmed">38494134</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre R. S., Durgam S., Huo J., Kozauer S. G., Stahl S. M. (2023). The efficacy of lumateperone in patients with bipolar depression with mixed features. J. Clin. Psychiatry 84 (3), 22m14739. 10.4088/JCP.22m14739</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.22m14739</ArticleId><ArticleId IdType="pubmed">37103915</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra B. R., Biswas T., Sreeraj V. S., Nath S., Mohapatra D., Maiti R. (2023). Paroxysmal dystonia and psychotic exacerbations in chronic psychosis: diagnostic dilemmas and preliminary treatment approaches. Br. J. Clin. Pharmacol. 89 (9), 2926–2932. 10.1111/bcp.15777</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15777</ArticleId><ArticleId IdType="pubmed">37160681</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S., Miyake N., Jarskog L. F., Fleischhacker W. W., Lieberman J. A. (2012). Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17 (12), 1206–1227. 10.1038/mp.2012.47</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.47</ArticleId><ArticleId IdType="pubmed">22584864</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder T. A. M., van Eerden R. A. G., de With M., Elens L., Hesselink D. A., Matic M., et al. (2021). CYP3A4∗22 genotyping in clinical practice: ready for implementation? Front. Genet. 12, 711943. 10.3389/fgene.2021.711943</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.711943</ArticleId><ArticleId IdType="pmc">PMC8296839</ArticleId><ArticleId IdType="pubmed">34306041</ArticleId></ArticleIdList></Reference><Reference><Citation>Orsolini L., De Berardis D., Volpe U. (2020). Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opin. Drug Saf. 19 (8), 981–998. 10.1080/14740338.2020.1795126</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2020.1795126</ArticleId><ArticleId IdType="pubmed">32657173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilla Reddy V., Kozielska M., Suleiman A. A., Johnson M., Vermeulen A., Liu J., et al. (2013). Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score. Schizophr. Res. 146 (1-3), 153–161. 10.1016/j.schres.2013.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.schres.2013.02.010</ArticleId><ArticleId IdType="pubmed">23473811</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeman M. V. (2004). Gender differences in the prescribing of antipsychotic drugs. Am. J. Psychiatry 161 (8), 1324–1333. 10.1176/appi.ajp.161.8.1324</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.161.8.1324</ArticleId><ArticleId IdType="pubmed">15285956</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder G. L., Vanover K. E., Zhu H., Miller D. B., O'Callaghan J. P., Tomesch J., et al. (2015). Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacol. Berl. 232 (3), 605–621. 10.1007/s00213-014-3704-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-014-3704-1</ArticleId><ArticleId IdType="pmc">PMC4302236</ArticleId><ArticleId IdType="pubmed">25120104</ArticleId></ArticleIdList></Reference><Reference><Citation>Solmi M., Seitidis G., Mavridis D., Correll C. U., Dragioti E., Guimond S., et al. (2023). Incidence, prevalence, and global burden of schizophrenia - data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol. Psychiatry 28 (12), 5319–5327. 10.1038/s41380-023-02138-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-023-02138-4</ArticleId><ArticleId IdType="pubmed">37500825</ArticleId></ArticleIdList></Reference><Reference><Citation>Sørup F. K. H., Eriksson R., Westergaard D., Hallas J., Brunak S., Ejdrup A. S. (2020). Sex differences in text-mined possible adverse drug events associated with drugs for psychosis. J. Psychopharmacol. 34 (5), 532–539. 10.1177/0269881120903466</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881120903466</ArticleId><ArticleId IdType="pubmed">32048538</ArticleId></ArticleIdList></Reference><Reference><Citation>Stassen H. H., Bachmann S., Bridler R., Cattapan K., Herzig D., Schneeberger A., et al. (2022). Detailing the effects of polypharmacy in psychiatry: longitudinal study of 320 patients hospitalized for depression or schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 272 (4), 603–619. 10.1007/s00406-021-01358-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-021-01358-5</ArticleId><ArticleId IdType="pmc">PMC9095543</ArticleId><ArticleId IdType="pubmed">34822007</ArticleId></ArticleIdList></Reference><Reference><Citation>Szarfman A., Machado S. G., O'Neill R. T. (2002). Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 25 (6), 381–392. 10.2165/00002018-200225060-00001</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200225060-00001</ArticleId><ArticleId IdType="pubmed">12071774</ArticleId></ArticleIdList></Reference><Reference><Citation>van Puijenbroek E. P., Bate A., Leufkens H. G., Lindquist M., Orre R., Egberts A. C. (2002). A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 11 (1), 3–10. 10.1002/pds.668</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.668</ArticleId><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Wang M., Li W., Wang X. (2024). A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system. Front. Pharmacol. 15, 1408135. 10.3389/fphar.2024.1408135</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2024.1408135</ArticleId><ArticleId IdType="pmc">PMC11208458</ArticleId><ArticleId IdType="pubmed">38939844</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Wei M., Zhang J. (2023). A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib. Front. Pharmacol. 14, 1200254. 10.3389/fphar.2023.1200254</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1200254</ArticleId><ArticleId IdType="pmc">PMC10469920</ArticleId><ArticleId IdType="pubmed">37663269</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>